NCI Explores AI to Screen For and Treat Pancreatic Cancer
The institute sees the emerging technology supporting treatment for patients by better controlling tumor growth.
A new initiative at the National Cancer Institute aims to create capabilities for detecting pancreatic cancer early and improving treatments for patients with mutations.
A big challenge with pancreatic cancer resides in the KRAS gene. When mutated, the gene can cause normal cells to become cancerous. A new therapy involving KRAS inhibitors and genetic testing can help patients screen for this earlier.
Dr. Christine Alewine, the NIH Lasker Scholar in the Laboratory of Molecular Biology at NCI’s Center for Cancer Research, discussed this breakthrough, how new advancements can serve as an alternative treatment for chemotherapy and where AI can make an impact. Plus, she notes how other health issues such as diabetes also plays a role in screening for pancreatic cancer.
-
Dr. Christine Alewine NIH Lasker Scholar in the Laboratory of Molecular Biology, Center for Cancer Research NCI
-
FDA Outlines Future Tech Priorities
FDA is advancing its tech capabilities with quantum computing, zero-trust architecture and modernized data sharing.
6m read -
GenAI Remains Top Focus for Public Sector IT Leaders
Federal leaders say generative AI is showing promise for efficiency in multiple use cases and sectors, including cancer research.
5m read -
This Partnership is Tackling Federal Zero Trust, Cloud Security
Industry leaders share insights on the critical role industry partnerships have in enabling government agencies to navigate procurement challenges for cloud and zero trust solutions.
16m watch Partner Content -
GenAI Automates Space Force Data Discovery
Space Force’s Will Haskell discusses GenAI advancements that are streamlining data access and analysis and enhancing workflows.
2m read